NextCure Inc (NXTC)
NASDAQ:NXTC
Want to see NXTC full AI Analyst Report?
NXTC Stock Chart & Stats
$13.73
-$0.05(-5.92%)
At close: 4:00 PM EST
$13.73
-$0.05(-5.92%)
Day’s Range― - ―
52-Week Range$1.78 - $15.74
Previous CloseN/A
Volume33.57K
Average Volume (3M)37.58K
Market Cap
$7.30M
Enterprise Value-$4.35M
Total Cash (Recent Filing)$29.74M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Jul 30, 2026EPS Estimate
-1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.07
Shares Outstanding3,612,096
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.36
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$20.00Price Target Upside45.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase 1 SIM0505 EfficacyRobust Phase 1 efficacy (55% ORR in defined dose cohorts) is a durable validation of the lead ADC's biology and target engagement. If reproducible in dose‑optimization and later trials, it materially de‑risks the program, strengthens partnering prospects and underpins long‑term pipeline value.
Low Leverage Reduces Solvency RiskModest reported leverage (debt-to-equity ~0.15) lowers near‑term refinancing and solvency pressure, giving management financial flexibility to prioritize clinical development over debt service. This structural balance sheet strength reduces bankruptcy risk while programs advance.
Narrowing Losses And Improving Cash TrendsTrailing results show narrowing operating losses and improvement in cash flow trends versus prior years, indicating better cost control or program prioritization. Sustained improvement extends runway and reduces dilution risk if maintained through next clinical milestones.
Bears Say
No Revenue; Sustained Large LossesThe company remains pre‑revenue with persistent, sizable net losses, preventing self‑funding of operations. This structural lack of revenue keeps long‑term profitability uncertain and makes future investment returns contingent on clinical success or out‑licensing.
Material Negative Operating And Free Cash FlowConsistently negative operating and free cash flow reflects ongoing cash consumption to fund trials and R&D. This structural cash burn necessitates external financing, increasing dilution risk and potentially constraining strategic choices around trial pace or partnership timing.
Finite Cash Runway Into Q1 2027A declared cash runway into Q1 2027 creates a clear near‑term funding cliff that can force dilutive financing or strategic deals. This timing risk is structural: major trial readouts or dose‑optimization milestones must align with financing cadence to avoid disruption to development plans.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $1.78 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $7.30M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Jul 30, 2026 which is in 40 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Apr 30, 2026. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$2.105 by $0.235.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -1.92.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 3,612,096 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$1.87 in its last earnings report, beating expectations of -$2.105. Following the earnings report the stock price went up 3.02%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
NXTC Stock 12 Month Forecast
Average Price Target
$20.00
▲(45.67% Upside)
Technical Analysis
Ownership Overview
―
Insiders
9.96% Mutual Funds
48.82% Other Institutional Investors
36.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---